Paul A Bunn

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. doi request reprint Worldwide overview of the current status of lung cancer diagnosis and treatment
    Paul A Bunn
    Division of Medical Oncology, University of Colorado, Aurora, CO 80045, USA
    Arch Pathol Lab Med 136:1478-81. 2012
  2. pmc Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
    Andrew J Weickhardt
    Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Colorado 80045, USA
    J Thorac Oncol 7:1807-14. 2012
  3. pmc Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression
    Rafal Dziadziuszko
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 28:2174-80. 2010
  4. ncbi request reprint Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 24:5034-42. 2006
  5. ncbi request reprint Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels
    Barbara A Helfrich
    Tobacco Related Malignancy Program, University of Colorado Cancer Center, Aurora, CO 80010, USA
    Clin Cancer Res 12:7117-25. 2006
  6. pmc EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort
    Marileila Varella-Garcia
    University of Colorado Cancer Center, Department of Medicine and Pathology, Aurora, CO 80045, USA
    J Thorac Oncol 4:318-25. 2009
  7. pmc Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, Aurora, CO 80045, USA
    Clin Cancer Res 14:6317-23. 2008
  8. pmc Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer
    Fred R Hirsch
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA
    Cancer 112:1114-21. 2008
  9. doi request reprint First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay
    Fred R Hirsch
    Division of Medical Oncology, University of Colorado, Health Sciences Center, Aurora, CO, USA
    J Thorac Oncol 3:S138-42. 2008
  10. ncbi request reprint Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report
    Rafal Dziadziuszko
    Department of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA
    J Thorac Oncol 2:91-2. 2007

Detail Information

Publications36

  1. doi request reprint Worldwide overview of the current status of lung cancer diagnosis and treatment
    Paul A Bunn
    Division of Medical Oncology, University of Colorado, Aurora, CO 80045, USA
    Arch Pathol Lab Med 136:1478-81. 2012
    ..An increasing percentage of patients with advanced lung cancer have molecular drivers in genes for which oral tyrosine kinase inhibitors have been developed...
  2. pmc Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
    Andrew J Weickhardt
    Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Colorado 80045, USA
    J Thorac Oncol 7:1807-14. 2012
    ....
  3. pmc Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression
    Rafal Dziadziuszko
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 28:2174-80. 2010
    ....
  4. ncbi request reprint Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 24:5034-42. 2006
    ..We analyzed ISEL tumor biopsy samples to examine relationships between biomarkers and clinical outcome after gefitinib treatment in a placebo-controlled setting...
  5. ncbi request reprint Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels
    Barbara A Helfrich
    Tobacco Related Malignancy Program, University of Colorado Cancer Center, Aurora, CO 80010, USA
    Clin Cancer Res 12:7117-25. 2006
    ..Downstream cell cycle and signaling events were compared with growth-inhibitory effects...
  6. pmc EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort
    Marileila Varella-Garcia
    University of Colorado Cancer Center, Department of Medicine and Pathology, Aurora, CO 80045, USA
    J Thorac Oncol 4:318-25. 2009
    ..This study was carried out to verify whether EGFR FISH had similar performance in Japanese patients...
  7. pmc Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, Aurora, CO 80045, USA
    Clin Cancer Res 14:6317-23. 2008
    ..Methods: EGFR FISH analysis was done using LSI EGFR SpectrumOrange/CEP7 SpectrumGreen probe...
  8. pmc Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer
    Fred R Hirsch
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA
    Cancer 112:1114-21. 2008
    ..Two different antibodies, scoring systems, and cutoff points of epidermal growth factor receptor (EGFR) protein expression were compared to predict response and survival of enrolled patients...
  9. doi request reprint First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay
    Fred R Hirsch
    Division of Medical Oncology, University of Colorado, Health Sciences Center, Aurora, CO, USA
    J Thorac Oncol 3:S138-42. 2008
    ....
  10. ncbi request reprint Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report
    Rafal Dziadziuszko
    Department of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA
    J Thorac Oncol 2:91-2. 2007
    ..Molecular characterization of the primary tumor before any treatment is provided, and mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors are briefly discussed...
  11. pmc A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, 12801 E 17th Ave, Aurora, CO 80045, USA
    J Clin Oncol 29:3567-73. 2011
    ....
  12. ncbi request reprint Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer
    Glen J Weiss
    Division of Medical Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Clin Lung Cancer 8:335-8. 2007
    ..The addition of bevacizumab to carboplatin/paclitaxel in the first-line setting was shown to improve survival and response. We assessed pemetrexed and bevacizumab compared with pemetrexed alone in the salvage setting...
  13. ncbi request reprint Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma
    Barbara A Frederick
    Departments of Radiation, University of Colorado at Denver Health Sciences Center, Aurora, Colorado 80010, USA
    Mol Cancer Ther 6:1683-91. 2007
    ....
  14. ncbi request reprint Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy
    Paul A Bunn
    Department of Medicine, University of Colorado Cancer Center and University of Colorado Health Sciences Center, Aurora, 80045, USA
    Clin Cancer Res 12:3652-6. 2006
  15. pmc Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
    Andrew J Weickhardt
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
    Cancer 119:2383-90. 2013
    ..The detailed etiology of the effect, its symptomatic significance, and the effectiveness of subsequent testosterone replacement have not been previously reported...
  16. doi request reprint New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
    Robert C Doebele
    University of Colorado Cancer Center, Division of Medical Oncology, Aurora, CO, USA
    Lung Cancer 69:1-12. 2010
    ....
  17. ncbi request reprint Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer
    Rafal Dziadziuszko
    University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Clin Cancer Res 12:3078-84. 2006
    ....
  18. doi request reprint Endobronchial miRNAs as biomarkers in lung cancer chemoprevention
    Celine Mascaux
    Department of Medicine, Division of Medical Oncology, Colorado School of Public Health, Aurora, 80045, USA
    Cancer Prev Res (Phila) 6:100-8. 2013
    ..Mir-34c changes at follow-up could be used as a quantitative biomarker that parallels histologic response in formalin-fixed bronchial biopsies in future lung cancer chemoprevention studies...
  19. pmc Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
    Robert C Doebele
    Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4502-11. 2012
    ..It is hypothesized that the dominant oncogene in NSCLC would be associated with distinct patterns of metastatic spread in NSCLC at the time of diagnosis...
  20. doi request reprint Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy
    Samir E Witta
    University of Colorado Cancer Center, 12801 E 17th Ave, Mail Stop 8117, Aurora, CO 80045, USA
    J Clin Oncol 30:2248-55. 2012
    ..This randomized phase II study evaluated the outcome of erlotinib with and without the isoform selective HDACi, entinostat...
  21. doi request reprint Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion
    Paul A Bunn
    University of Colorado Cancer Center, Aurora, Colorado, USA
    Oncologist 13:37-46. 2008
    ....
  22. ncbi request reprint From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer
    Glen J Weiss
    Developmental Therapeutics Program, Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA
    Oncology (Williston Park) 20:1515-24; discussion 1524-5, 1530, 1535. 2006
    ..Together, these developments have moved us away from the nihilism of 20 years ago into an era of unprecedented optimism in taking on the many remaining challenges of managing NSCLC in the 21st century...
  23. doi request reprint Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction
    Paul A Bunn
    University of Colorado Cancer Center, Aurora, Colorado, USA
    Oncologist 13:1-4. 2008
    ..In fact, many commonly used chemotherapeutic drugs have antiangiogenic activity. Ongoing studies are focusing on patient selection and targeted therapies, and there are many new agents undergoing clinical trials...
  24. doi request reprint Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity
    Tim Byers
    School of Medicine, University of Colorado Comprehensive Cancer Center, 13001 East 17th Place, Aurora, CO 80045, USA
    Cancer Epidemiol Biomarkers Prev 17:158-62. 2008
    ..Radiologic imaging may be more sensitive for peripheral cancers than for cancers arising in the central airways, from which bronchial epithelial cells are exfoliated into the sputum...
  25. ncbi request reprint Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer
    Glen J Weiss
    University of Colorado Health Sciences Center, Division of Medical Oncology Center, Aurora, CO 80010, USA
    J Clin Oncol 24:4405-11. 2006
    ..However, few published data exist on the efficacy and tolerability of second-line cytotoxic therapy in this population...
  26. pmc Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition
    Matias Casás-Selves
    Department of Biochemistry and Molecular Genetics, Program in Molecular Biology, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
    Cancer Res 72:4154-64. 2012
    ..Targeting the Wnt-tankyrase-β-catenin pathway together with EGFR inhibition may improve clinical outcome in patients with NSCLC...
  27. ncbi request reprint Early-stage NSCLC: the role of radiotherapy and systemic therapy
    Paul A Bunn
    Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Denver, Colorado 80045, USA
    J Natl Compr Canc Netw 2:S31-40. 2004
    ..Ongoing trials continue to assess the role of preoperative and postoperative chemotherapy or radiotherapy in early stage non-small cell lung cancer...
  28. pmc Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells
    Lindsay Marek
    Department of Craniofacial Biology, University of Colorado at Denver Anschutz Medical Campus, Aurora, CO 80045, USA
    Mol Pharmacol 75:196-207. 2009
    ..Thus, FGF2, FGF9 and their respective high-affinity FGFRs comprise a growth factor autocrine loop that is active in a subset of gefitinib-insensitive NSCLC cell lines...
  29. doi request reprint The tissue is the issue: personalized medicine for non-small cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Clin Cancer Res 16:4909-11. 2010
    ..Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed...
  30. ncbi request reprint Adjuvant chemotherapy for resected non-small-cell lung cancer
    Benjamin Solomon
    Medical Oncology Fellow, University of Colorado, Health Sciences Center, Denver, USA
    Oncology (Williston Park) 19:1685-97; discussion 1698-700, 1705. 2005
    ....
  31. ncbi request reprint Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
    Thomas J Lynch
    Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
    Clin Cancer Res 12:4365s-4371s. 2006
  32. doi request reprint Volatile fingerprints of cancer specific genetic mutations
    Nir Peled
    Thoracic Cancer Research and Detection Center, Sheba Medical Center, Tel Hashomer, Tel Aviv, Israel University of Colorado Cancer Center, Aurora, CO, USA
    Nanomedicine 9:758-66. 2013
    ..Studying clinical samples (tissue/blood/breath) will be required as next step in order to determine whether this cell-line study can be translated into a clinically useful tool...
  33. ncbi request reprint Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent
    Benjamin Solomon
    University of Colorado Cancer Center, Aurora, CO 80045, USA
    Future Oncol 1:733-46. 2005
    ..Clinical trials of pemetrexed alone or in combination with other chemotherapeutic agents have shown considerable activity in many tumor types including colorectal, pancreatic and breast cancer, and urothelial tumors...
  34. ncbi request reprint Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
    Samir E Witta
    Department of Medicine Medical Oncology, University of Colorado Health Sciences Center and University of Colorado Cancer Center, Campus Box 8117, PO Box 6511, Aurora, CO 80045, USA
    Cancer Res 66:944-50. 2006
    ..Thus, combined HDAC inhibitor and gefitinib treatment represents a novel pharmacologic strategy for overcoming resistance to EGFR inhibitors in patients with lung cancer...
  35. ncbi request reprint Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients
    Federico Cappuzzo
    University of Colorado Cancer Center, Department of Medicine and Pathology, Aurora, CO 80010, USA
    J Clin Oncol 23:5007-18. 2005
    ..Preclinical data indicate that HER2, a member of the EGFR family, could enhance TKI sensitivity...
  36. ncbi request reprint Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer
    Christiane D Thienelt
    Division of Medical Oncology and Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    J Clin Oncol 23:8786-93. 2005
    ..Secondary objectives included efficacy and paclitaxel and carboplatin pharmacokinetics during cetuximab treatment...